CAR Stock Recent News

Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024.

Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption  Kyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritis EMERYVILLE, Calif. , June 10, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled "Chimeric antigen receptor T cell therapy for autoimmune disease"1.

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) --

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. Findings demon.

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association's (EHA) Hybrid Congress. Data from Cohort D of the Ph.

Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif. , May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA , May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy, for the treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). "Dosing of the first patient in the CT-0525 Phase 1 trial is a significant step in the development of engineered myeloid cells, marking the first time a CAR-Monocyte is tested in humans in the solid tumor setting," said Eugene P.

Canadian Apartment Properties Real Estate Investment Trust (OTC:CDPYF) Q1 2024 Earnings Conference Call May 9, 2024 9:00 AM ET Company Participants Nicole Dolan - Investor Relations Mark Kenney - President & Chief Executive Officer Julian Schonfeldt - Chief Investment Officer Stephen Co - Chief Financial Officer Conference Call Participants Jonathan Kelcher - TD Cowen Kyle Stanley - Desjardins Capital Markets Mike Markidis - BMO Capital Markets Jimmy Shan - RBC Capital Markets Sairam Srinivas - Cormark Securities Matt Kornack - National Bank of Canada Financial Markets Operator Good morning. Thank you for attending today's Canadian Apartment Properties REIT First Quarter 2024 Results conference call.